BIC of CERN selects Arc Power and Terapet as new incubatees

Please login or
register
17.10.2019
Arc Power, Terpaet

Arc Power, developer of radiation-resistant electronics for space, and Terapet with its high-precision PET scanner to increase the efficiency of proton therapy have each received a cash grant of CHF 50'000. The two startups will now start the two-year entrepreneurship program of the Swiss BIC of CERN Technologies.

Swiss BIC of CERN Technologies offers a two-year entrepreneurship program to support high tech startups in implementing their ideas. During the incubation, participants benefit from a wide range of offers including access to accelerator technology expertise.

Yesterday, the second edition of the program started with a pitching event where five startups presented their business ideas to the audience and the selection committee. Out of five participating startups, only companies convinced the jury of the potential of their solutions. Each winner received a cash grant of CHF 50'000 in addition to non-monetary benefits such as licensing agreements with CERN and the PSI, continuous business and technical support, and an awareness boost.

The winners are

Arc Power GmbH
Incorporated in 2016 and co-founded by Mattia Vecchiarelli and Alessandro Contissa, Arc Power developed the first European hybrid DC/DC converter for space utilization. Not only is it radiation-resistant, but it is also composed of only European components and complies with the European Space Agency (ESA) standards. The company will design and manufacture the converter within Europe and under ESA supervision.

"The BIC of CERN Technologies award establishes our company more firmly within Switzerland’s technological environment and also within the space industry. The geographical proximity to Paul Scherrer Institute PSI will facilitate our collaboration with other start-up companies. We greatly value the access provided to CERN Intellectual Property, as the space environment is very competitive”, said Mattia Vecchiarelli (Co-Founder).

TERAPET – founded in 2019, aims to play a key role in advancing the development and future growth of proton therapy. Their non-invasive medical device is able to trace the applied dose of proton therapy and measure its precise location in 3D, in real-time and in vivo, thus decimating the risk of side effects and secondary cancers while enabling faster treatment at a reduced cost. 

The team comprising Christina Vallgren, Marcus Palm and Prof. Raymond Miralbellthe has recently rceived CHF 100'000 from the FIT Seed loan and now plans to build the first prototype within the Innosuisse Framework together with the CERN Crystal laboratory experts. This prototype will be a double-headed PET scanner.

“This award is an important milestone for us, which we absolutely wanted to achieve - cooperation with CERN. With this award, we are now also closer to the Paul Scherrer Institute PSI and its proton therapy centre. With our technology, proton therapy treatment can become even more precise, and thus cheaper”, said Cristina Vallgren, Marcus Palm.

The selection committee comprised of all partners of Swiss BIC of CERN Technologies such as CERNPARK INNOVAARE, the Paul Scherrer Institute PSI, and the University of Applied Sciences Northwestern Switzerland (FHNW). Additionally, three independent experts from the fields of Intellectual Property (IP), finance and industry sit on the committee.

(Press release/ran)

Photo L-R:
Dr. Benno Rechsteiner (CEO innovAARE AG) & Mattia Vecchiarelli, CEO Arc Power, Christina Vallgren und Dr. Marcus Palm, CEOs of Terapet.

0Comments

More news about

Arc Power GmbH

Terapet SA

Company profiles on startup.ch

Arc Power GmbH

Terapet SA

rss